{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-254698","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.239174+00:00","generated_at":"2026-05-17T01:44:52.448865+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"low","headline":"Kyverna reports positive interim Phase 2 data for KYV-101 in generalized myasthenia gravis","bullets":["Positive interim data from Phase 2 portion of KYSA-6 trial of KYV-101 announced on October 29, 2025.","Conference call held same day at 8 a.m. Eastern Time to discuss results; slides furnished as Exhibit 99.1.","No specific efficacy or safety figures included in the filing text; detailed data in attached slide deck.","Kyverna is a clinical-stage biotech focused on CAR T-cell therapies for autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-254698","json":"https://secwatch.observer/filing/0001193125-25-254698.json","markdown":"https://secwatch.observer/filing/0001193125-25-254698.md","text":"https://secwatch.observer/filing/0001193125-25-254698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525254698/0001193125-25-254698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312525254698/d59631d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:44:52.448865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}